TNB-738 / TeneoFour, Inc, Ancora Biotech - LARVOL DELTA

A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=31 | Completed | Sponsor: TeneoFour Inc. | Recruiting ➔ Completed | N=80 ➔ 31 | Trial completion date: Aug 2024 ➔ Jul 2023 | Trial primary completion date: Jan 2024 ➔ May 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date

A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: TeneoFour Inc. | Trial completion date: Mar 2023 ➔ Aug 2024 | Trial primary completion date: Dec 2022 ➔ Jan 2024

Trial completion date • Trial primary completion date

Targeting CD38 in Neoplasms and Non-Cancer Diseases. (PubMed, Cancers (Basel)) - "Daratumumab and isatuximab already received FDA approval, and novel agents such as MOR202, TAK079 and TNB-738 undergo clinical trials. Also, novel therapeutics such as SAR442085 aim to outrank the older antibodies against CD38...This review focuses on targeting CD38 in cancer and non-cancerous diseases using antibodies, cell-based therapies and CD38 inhibitors. We also provide a summary of current clinical trials targeting CD38."

IO biomarker • Journal • Review • Amyloidosis • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lymphoma • Multiple Myeloma • Novel Coronavirus Disease • Oncology • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • Transplant Rejection • Transplantation • CD19

A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: TeneoFour Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity. (PubMed, MAbs) - "Due to its silenced IgG4 Fc, TNB-738 did not deplete CD38-expressing cells, in contrast to the clinically available anti-CD38 antibodies, daratumumab, and isatuximab. TNB-738 offers numerous advantages compared to other NAD-boosting therapeutics, including small molecules, and supplements, due to its long half-life, specificity, safety profile, and activity. Overall, TNB-738 represents a novel treatment with broad therapeutic potential for metabolic and inflammatory diseases associated with NAD+ deficiencies.Abbreviations: 7-AAD: 7-aminoactinomycin D; ADCC: antibody dependent cell-mediated cytotoxicity; ADCP: antibody dependent cell-mediated phagocytosis; ADPR: adenosine diphosphate ribose; APC: allophycocyanin; cADPR: cyclic ADP-ribose; cDNA: complementary DNA; BSA: bovine serum albumin; CD38: cluster of differentiation 38; CDC: complement dependent cytotoxicity; CFA: Freund's complete adjuvant; CHO: Chinese hamster ovary; CCP4: collaborative computational project,..."

IO biomarker • Journal • CNS Disorders • Inflammation • EGF • IFNG • PARP1

A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: TeneoFour Inc.

New P1 trial

Newly-Formed Ancora Biotech Will Continue Operations of Teneobio Spin-offs After Successful Acquisition of Teneobio by Amgen (Businesswire) - "Ancora Biotech announced, in connection with the closing of the acquisition of Teneobio, Inc., by Amgen Inc., that Teneobio’s former shareholders and their representatives will provide oversight of three previous affiliates of Teneobio, including TeneoTwo, Inc. (TNB-486, anti-CD19xCD3), TeneoFour, Inc. (anti-CD38 enzyme inhibitor TNB-738)...while TeneoFour’s TNB-738, targeting inflammatory diseases, will enter Phase I in early 2022."

M&A • New P1 trial • Hepatitis B • Infectious Disease